ITERBIL®

Azacitidine 100 mg. Lyophilized powder for injectables

Therapeutical classification:

Antineoplásico.

How supplied:

Lyophilized powder in 100 mg single-use vials packaged in cartons of 1 vial.

Indications:

Dosage and administration:

First treatment cycle: The recommended starting dose for the first treatment cycle, is 75 mg/m² daily for 7 days to be administered by subcutaneous injection or intravenous infusion.

Following treatment  cycles: Repeat cycles every 4 weeks. After 2 cycles, may increase dose to 100 mg/m²  if no beneficial effect is seen and no toxicity other than nausea and vomiting has occurred. Patients should be treated for a minimum of 4 to 6 cycles. Complete or partial response may require additional treatment cycles.

Continue treatment as long as the patient continues to benefit.

For further information read the complete prospect.

Storage:

Storage at room temperature between 15 °C and 30 °C.